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Purpose: This study investigates (i) the effect of verification protocols on treatment 1 
accuracy and PTV margins for partial breast and boost breast radiotherapy with short 2 
fractionation schema (15 fractions), (ii) the effect of deformation of the excision cavity 3 
(EC) on PTV margin size, (iii) the imaging dose required to achieve specific PTV 4 
margins.  5 
 6 
Methods and Materials: Verification images using implanted EC markers were studied 7 
in 36 patients. Target motion was estimated for a 15 fraction partial breast regimen using 8 
imaging protocols based on-line and off-line motion correction strategies (No Action 9 
Level (NAL) and the extended NAL (eNAL) protocols). Target motion was used to 10 
estimate a PTV margin for each protocol.  To evaluate treatment errors due to 11 
deformation of the excision cavity, individual marker positions were obtained from 11 12 
patients. The mean clip displacement and daily variation in clip position during 13 
radiotherapy were determined and the contribution of these errors to PTV margin 14 
calculated. Published imaging dose data were used to estimate total dose for each 15 
protocol. Finally the number of images required to obtain a specific PTV margin was 16 
evaluated and hence, the relationship between PTV margins and imaging dose was 17 
investigated.   18 
 19 
Results: The PTV margin required to account for excision cavity motion, varied between 20 
10.2mm and 2.4mm depending on the correction strategy used. Average clip movement 21 
was 0.8mm and average variation in clip position during treatment was 0.4mm. The 22 
contribution to PTV margin from deformation was estimated to be small  less than 23 
0.2mm for both off-line and on-line correction protocols. 24 
 25 
 5 
 
Conclusion: A boost or partial breast PTV margin of ~10mm, is possible with zero 1 
imaging dose and workload, however, patients receiving boost radiotherapy may benefit 2 
from a margin reduction of ~4mm with imaging doses from 0.4cGy to 25cGy using an 3 
eNAL protocol. PTV margin contributions from deformation errors are likely to be small in 4 
comparison to other sources of error, i.e., set up or delineation. 5 
 6 
 7 
Keywords: partial breast radiotherapy; fiducial markers; imaging dose; verification 8 
protocols; image-guided radiotherapy.9 
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Introduction 1 
 2 
Typical radiotherapy regimens for patients undergoing breast conservation therapy are 45 to 3 
50Gy delivered to the whole breast in daily 1.8 to 2Gy fractions over 5 or 6 weeks with or without 4 
a boost dose to the excision cavity.  There is increasing evidence to support the introduction of 5 
strategies to tailor patients’ treatment to their risk of local recurrence. Excision cavity boosts have 6 
been shown to reduce the risk of recurrence and in patients of high risk of recurrence 7 
simultaneous integrated boost (SIB) to the excision cavity is appropriate (1).  For patients at low 8 
risk of recurrence, modest dose reduction to non-target tissue away from the excision cavity is 9 
expected to reduce complications without compromising tumour control because the risk of 10 
recurrence is highest in the index quadrant (1).  Furthermore, the observation that a modest 11 
increase in fraction size accompanied by a decrease in total dose is likely to result in equivalent 12 
local control (2) has led to the re-introduction of hypofractioned breast treatment.  Accelerated 13 
partial breast irradiation (APBI) delivered in 10 fractions is currently being investigated in the 14 
NSABP/RTOG-0413 phase-III trials in the United States and in the UK, the IMPORT phase III 15 
trials (3) are exploring the effects of reducing radiation dose to low risk volumes in both high and 16 
low risk patients groups using a 15 fraction regime (3).   17 
 18 
Work by de Boer et al (4, 5) has shown that it is possible to reduce set up errors without the need 19 
for daily imaging. They introduced imaging verification protocols (No Action Level and extended 20 
No Action Level) that only require between 3 and 9 images for a 35 fraction treatment thus 21 
decreasing both concomitant dose and workload to acceptable levels.  22 
Markers implanted into the breast at lumpectomy reduce patient motion errors for the partial 23 
breast or boost PTVs and hence improve accuracy of treatment. Depending on the availability of 24 
imaging equipment and type of markers used, gold seeds or surgical clips, marker-based image 25 
guidance may require 3D imaging which will impart higher concomitant doses.   26 
 27 
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Despite the improvements afforded by marker-based IGRT, deformation of the excision cavity is 1 
of particular concern in partial breast and breast boost radiotherapy where the PTV is determined 2 
by the addition of margins to the excision cavity delineated at the time of planning.  We and other 3 
authors (6-8 ) have reported on changes in size and shape of the excision cavity that occur during 4 
treatment.  These studies have measured the changes but have not investigated how these 5 
changes could reduce treatment accuracy and if so how PTV margins should be adjusted 6 
accordingly to account for this type of target motion, which this study attempts to do   7 
 8 
The purpose of this work is to investigate the following:  9 
• The effect of using established imaging verification protocols on PTV margins in a 15 10 
fraction treatment regimen.  11 
•  The effect of deformation on margin size  12 
• The variation of PTV margin size with imaging dose 13 
 14 
Methods 15 
Fifty-three patients were recruited from four UK radiotherapy centres (centres A, B, C 16 
and D) for the Gold Seed feasibility study; a full description of this study is given by 17 
Coles et al. (9). Briefly, following wide local excision of the primary tumour, patients 18 
received six gold markers (diameter 3mm; thickness 1mm: hole diameter 1mm). Markers 19 
were sutured onto walls of the excision cavity (medial, lateral, superior and inferior 20 
aspects) prior to any breast remodelling. In this work two subsets of these data were 21 
used. The first was a subset of 36 patient datasets from patients who received a 22 
minimum of 12 imaging sessions. This enabled imaging verification protocols to be 23 
simulated by sampling from the measured data and then using the whole data set to 24 
assess the net effect of the protocol. The second subset of patients datasets were those 25 
patients who were treated at centre C, a total of 11 patients. The names of the 26 
radiotherapy centres, the number of patients included are provided in Table 1. Of these 27 
 8 
 
11 patient, 4 had visible or highly visible seroma (9) and two had large volume changes 1 
(greater than 30% shrinkage) (6).  2 
 3 
Verification Imaging 4 
Patients were immobilised using a breast board, buttock support and arms were raised 5 
behind the head.  Prior to imaging, patients were set-up using orthogonal laser-6 
alignment with medial and lateral skin tattoos marked at the time of planning, and any 7 
isocentre shift was applied. Verification imaging was carried out for each patient to a 8 
maximum of 15 fractions of the total course.  Each centre had different verification 9 
equipment. B used kilovoltage (2D on-board kV imager), whereas A, C and D used 2D 10 
MV imaging. The 2D MV imaging used a pair of images at each imaging fraction: one 11 
using the treatment beam and one using a 10x10cm2 field with the gantry positioned 12 
orthogonal to the treatment beam. For 2D kV imaging orthogonal anterior and lateral 13 
images were acquired. Centres, A, B and D determine the movement of the gold marker 14 
using matching software that compared the position of the markers in the verification 15 
images with that in DRRs generated from the planning CT or simulation images. For 16 
centre C, in-house software (6) allowed the user to identify the position of each marker in 17 
the orthogonal images and calculate their 3D position using triangulation. The imaging 18 
equipment and analysis software used is given in Table1. Their centre of mass position 19 
was compared with that in the planning CT. All systems delivered an output which was 20 
the 3D daily displacement of the gold markers (representing excision cavity 21 
displacement) from the reference position at planning, hence the effective systematic 22 
and treatment execution (random) motion errors per patient as a function of time could 23 
be calculated. Daily positions of individual markers were determined for the subset of 11 24 
patients using the in-house software described above.  25 
 9 
 
 1 
Target motion  2 
Target motion data for the group of 36 patients were measured in the left-right (LR), 3 
superior-inferior (SI) and anterior-posterior (AP) directions respectively. Each patient 4 
dataset consisted of at least 12 displacements: 4 patients had 12, 1 patient had 13, 6 5 
patients had 14 for and 25 had 15. Shapiro-Wilk test was used to check that data were 6 
normally distributed. An ANOVA test was used to test for differences between data from 7 
each centre. There was no evidence that the distributions were significantly different, 8 
therefore the data were pooled to create a single dataset of 36 patients.  9 
 10 
The following correction protocols were modelled retrospectively to the measurement 11 
data from the 36 patients: 12 
• No correction 13 
• No Action Level (NAL) (4): mean set up error is determined from a fixed number 14 
of fractions. 15 
• Extended No Action Level (eNAL) (5): includes addition imaging fractions at 16 
regular intervals. 17 
• Daily on-line correction  18 
A measurement fraction is defined as one which is used to calculate a correction value. 19 
The whole patient dataset was then used to assess the effect of this correction. 20 
 21 
No correction 22 
No correction was applied based on the measurement data. 23 
 24 
NAL Protocol 25 
 10 
 
The correction value CNAL was the mean of the displacements measured at the first Nm 1 
fractions and applied on all subsequent fractions i.e. from fraction Nm+1. We investigated 2 
Nm values of 3, 4 and 5 (Table 2). For Nm values of 4 and 5, a correction based on the 3 
first 3 measurements was always applied on fraction 4 and updated after each additional 4 
measurement fraction. This rolling adjustment to the NAL protocol was necessary 5 
because of the relatively small number of treatment fractions (Nf). If the proportion of 6 
uncorrected fractions (Nm/Nf) becomes higher than ~0.3 systematic errors are expected 7 
to increase  (4).  8 
 9 
eNAL Protocol 10 
The eNAL approach started in the same way as the NAL protocol but the corrections 11 
CeNAL were updated at subsequent measurement fractions. They are summarised in 12 
table 2, where images are acquired for the first 3 fractions and ∆frep is the interval 13 
between subsequent measurement fractions and Ntot is the total number of imaged 14 
fractions (5).  15 
 16 
On line Correction 17 
All measurement data were used and each measurement fraction was corrected for the 18 
measured motion for that fraction.  19 
  20 
Post correction, a residual error, σr, is expected to remain due to factors such as the 21 
finite accuracy with which the correction was applied, surrogate error (i.e., error in cavity 22 
position after perfect set-up to clips), and the effects of breathing variations (the internal 23 
margin). From the literature (10,11) we have estimated σr  to have a random error 24 
component of 2mm (standard deviation); we assume that the systematic component of 25 
 11 
 
σr is zero. σr will act to increase the day to day variation in post-correction patient 1 
displacements. For each corrected fraction we added a correction error which was 2 
randomly sampled from a normal distribution with zero mean and 2mm standard 3 
deviation using Matlab (Mathworks, USA) .  4 
 5 
 6 
The impact on margins of correction protocols was evaluated using distributions of the 7 
patient motion errors post correction in each direction of motion. Both effective 8 
systematic (Σmot) and treatment execution errors (σmot) were calculated (6).  9 
 10 
 11 
Deformation of the excision cavity 12 
 13 
The magnitude of deformation of the excision cavity was estimated using the  marker 14 
positions from 11 patients. In the first instance the centre of mass (COM) of the markers 15 
at planning (day 0) and all imaging days (n = 1, …, Ntot) was calculated. Then COM 16 
correction was performed for all imaging days. Displacements δ(LR), δ(SI) and δ(AP), 17 
between day 0 and day N were measured for each individual marker. Marker movement 18 
toward the COM was recorded as a negative displacement and movement away from 19 
the COM as a positive displacement.  Further detail on these measurements is included 20 
an e-appendix.  21 
 22 
Following the same formulism as for treatment errors the following population variables 23 
were defined to describe the distribution of errors due to deformation:  24 
 12 
 
• Patient-specific deformation, µdef: all (µdef(all)) and positive (µdef(+ve)) mean marker 1 
displacements averaged across all imaging days and all markers.  2 
•  Patient-specific day-to-day deformation, ∆p: the mean daily variation in marker 3 
position averaged across all markers (∆p(all)) and those with positive mean 4 
displacements only (∆p(+ve)). The daily variation of a marker was defined as the 5 
standard deviation in marker displacement across all imaging days.  6 
• Effective systematic treatment
 
error, Σdef: the standard deviation of all µdef 7 
• The treatment execution error, σdef:  the mean of all ∆p.   8 
 9 
 10 
Effect of Correction Protocols on PTV Margins 11 
Calculated motion errors post correction were used to estimate a margin, Mmot for 12 
different correction protocols.  M was defined using (12):  13 
 14 
 = 2Σ + 0.7               (1) 15 
 16 
Additional total motion margin estimations (MTM) which include the effect of deformation 17 
were also determined. Total effective systematic and treatment execution errors were 18 
determined by adding motion and deformation errors in quadrature. Thus, MTM is found 19 
using:  20 
 21 
     22 
 13 
 
 = 2Σ + Σ		() + 0.7σ + σ		()                            1 
(2) 2 
 3 
We use the treatment errors derived using clips with positive mean displacements only, 4 
mean negative displacements are set to zero.  5 
 6 
Imaging Dose Data 7 
 8 
Estimates for the dose delivered were collated from published data (13-15). Doses given 9 
in the literature were measured using a variety of methods and measurement points. 10 
MVCT doses were derived from the number of monitor units delivered (13) and related 11 
to the calibration of the treatment machine typically 1cGy/MU at depth Dmax. Doses 12 
chosen from the literature for other imaging modalities were those measured at the 13 
surface of the patient (14) or phantom (15) as this was the closest measurement point to 14 
Dmax. The range of clinically used MVCT doses are reported to be 2 -10cGy by Morin et 15 
al. (13), however, to assess dose to specific organs they use a minimum exposure of 16 
5cGy and therefore we have used this value.  17 
 18 
For planar imaging doses we use data from Walter et al.(14) who present surface doses 19 
measured for anterior and lateral views. We have taken the mean dose of the two views. 20 
Published MV planar imaging doses were based on 5MU/image, we have adjusted the 21 
dose assuming 1MU/image which was used in the Gold Seed study (9). Table 3 22 
summaries the dose per image used in this study.  23 
24 
 14 
 
Results 1 
 2 
Analysis of the uncorrected patient data (Table 4) showed that the population effective 3 
systematic error (Σmot) was ~ 4.0 mm and the treatment execution error (σmot) ~ 2.7 mm. 4 
The effect on Σmot of the different correction protocols is seen in Table 5 with an on-line 5 
protocol producing the greatest reduction. Off-line protocols reduced effective systematic 6 
errors to between 2.0 and 1.3 mm depending upon the imaging frequency. Lower 7 
effective systematic errors were obtained using the eNAL rather than the NAL protocol 8 
however increasing the number of imaging days, Ntot, from 5 to 8 gave a relatively small 9 
reduction in Σmot(avg) of 0.3 mm.  10 
 11 
Table 4 shows data relating to the deformation of the excision cavity. When all 12 
displacements (towards and away from the COM) are considered the mean 13 
deformations µdef(all) are negative indicating that on average movements are toward the 14 
COM.   Both Σdef and σdef are smaller (less than 0.4 mm) when only positive motions only 15 
are considered.  For the 11 patients, 61 markers were investigated, of these 45 had 16 
mean positive displacements in at least one direction and 26 had greater than 2mm 3D 17 
movement (i.e., the magnitude of the displacement vector). Table 5 gives margin 18 
estimations for motion and total motion per correction protocol. The effect of deformation 19 
and rotation is to increase the margins by 0.2 mm when on-line imaging is used. This 20 
addition is ~ 0.1 mm if an off-line protocol is employed due to larger residual systematic 21 
motion error post corrections.  22 
 23 
Figure 1(a) shows the relationship between dose and Mmot and MTM. To achieve a 24 
specific margin, a higher number of images and hence a higher imaging dose is required 25 
 15 
 
to account for deformation. Figure 1(a) shows the relationship between mean total 1 
motion margin size (averaged over the three directions, see Table 3) and imaging dose 2 
for the different imaging systems when the range of error correction protocols was 3 
applied. The total imaging dose increased with complexity of correction, although not 4 
exceeding 2% of a typical 45Gy dose to the treated breast, even for the highest 5 
estimated dose. A margin of less than 6mm could be achieved post correction using the 6 
eNAL protocol. However, increasing Nm from 6 to 8 and hence increasing dose by 33% 7 
afforded little reduction in margin size.  8 
 9 
 10 
Discussion  11 
This study has shown that pre-correction effective systematic motion errors are 12 
approximately 4.0 mm in all directions which are similar to another study by Tolpolnjak et 13 
al.(16) who reported systematic errors of 3.0 mm, 3.8 mm and 2.7 mm in the left-right, 14 
superior-inferior and anterior-posterior directions.  PTV motion margins pre-correction 15 
are ~10.2 mm. The average estimated motion margin offers an indication of the relative 16 
decease in volume of normal tissue irradiated using the different correction protocols.  17 
An on-line protocol reduced the margins to less than 3 mm, at a cost in time and imaging 18 
dose however, this imaging dose can be as low as ~1.5cGy if kilovoltage 2D planar 19 
imaging is used.  20 
 21 
Penninkhof et al. (17) reported mean clip displacement during treatment of 0.9mm and 22 
average intrafraction motion 0.5mm and Topolnjak (18) found average clip motion from 23 
CT to end of treatment to be -1.4 ± 1.5 mm. These values are for the magnitude of the 24 
3D vector from the clip to the centre of mass. We found similar values for average 25 
displacements, -0.6, -0.8 and -0.5 mm and mean intrafraction variation 0.7, 0.6 and 0.8 26 
 16 
 
mm in the LR, SI and AP directions respectively.  Of our 11 patients 4 had seroma clarity 1 
score (SCS) > 2, Topolnjak et al. reported 3/21 with SCS > 2 (18).  Based on the 2 
assumption of a convex excision cavity, the negative sign implies shrinkage of the cavity 3 
(see e-appendix). Weed et al. (7) showed that, despite an overall shrinkage of the 4 
excision cavity deformation led to a proportion of the volume (defined during or after 5 
treatment) to fall outside of the volume defined at planning. Our estimation of suitable 6 
deformation errors used only those clips with positive mean displacements. If negative 7 
mean displacements are included the errors are greater (see table 4) however, these 8 
negative deformations will not lead to an underdosage of the target volume and should 9 
not act to increase the margin. Only positive displacements lead to underdosage of the 10 
target volume.   11 
Study Limitations:   12 
Set-up data were acquired using 2D imaging technologies. Others (19, 21) have found 13 
set-up errors measured using 2D imaging can be smaller than those measured using 3D 14 
imaging. The difference has been mainly attributed to poor visibility of the matching 15 
structure in portal images and the use of different parts of the anatomy for matching for 16 
the 2D and 3D techniques. For centres A, C and D the visualisation of gold marker in 17 
EPID images may be difficult if the markers overlay the rib cage and may have led to 18 
conservative set-up error estimation. However, no difference in set-up errors were 19 
observed for centre B (kV imaging) in comparison to the other centres. Penninkhof et al. 20 
(17) have compared 2D planar set-up errors with CBCT errors both based on clip match, 21 
the greatest difference was 1.1 mm in the AP direction, consequently we would not 22 
expect set-up errors of markers measured using 3D imaging to differ greatly from what 23 
we have observed.  24 
 25 
 17 
 
Delineation errors are not included in our margin calculation.  Other authors have 1 
proposed the inclusion of an error term in the margin formula to account for the variation 2 
in clinician delineation of the target volume (21). In this patient group, large clinician 3 
variation was observed (9) and distances between delineations exceeded 10mm.   We 4 
have included surrogate errors in our estimation of residual errors from the literature 5 
(10). Studies by Topolnjak et al. (18) and Weed et al. (7) show that markers are a good 6 
surrogate for the excision cavity, however, Topolnjak et al. reported residual systematic 7 
and treatment executions errors of ~1mm. Clearly, both delineation and surrogate errors 8 
are likely to be equally if not more important  than deformation errors.    9 
 10 
Rotations are not treated separately in this analysis. Where rotational set-up errors can 11 
be measured, i.e., using 3D imaging, local practice is to correct for large rotations (>5°) 12 
by repeating laser set-up. Rotations are not explicitly corrected i.e, there is no method 13 
available to rotate the patient. Clip motion due to rotation has been included in the 14 
deformation analysis. If small rotations could be accurately corrected for, these could be 15 
removed from the analysis and would have the effect of decreasing deformation errors.   16 
 17 
It is important to note that the imaging systems’ dose values from the literature are not 18 
specific for the case of breast irradiation and are measured in different ways, but they do 19 
provide an indication of the magnitude and range of the likely doses. The information 20 
available in a 2D image is inevitably less than that in a 3D image; a 3D image dataset 21 
may be used to track excision cavity soft-tissue deformation with time compared to the 22 
pre-treatment shape and size.  23 
 24 
Margins were used as an indication of treatment accuracy only. Most margin models 25 
assume motion errors are normally distributed (21). When using an off-line protocol, the 26 
 18 
 
patient motion set up error distribution has a step function because of the first 3 fraction 1 
correction. The margin formula used does not take into account that a proportion of the 2 
boost or partial breast dose may be delivered using the whole breast field. This will 3 
reduce the contribution of treatment execution errors to the required margin; the 4 
reduction being dependent on the specific treatment (21).  The analysis used is a 5 
simplification of how deformation will affect the CTV dose coverage. A more accurate 6 
estimation of motion margins would employ a model of treatment dose distribution, 7 
motion errors and a more accurate description of deformation. It is our intention to make 8 
a more precise estimate of the boost margins required once this data has becomes 9 
available from the IMPORT trial.  10 
 11 
 12 
Clinical relevance: It appears from our data that a modest level of verification imaging 13 
(e.g. a NAL protocol with 3 imaging sessions) would achieve the aim of checking the set 14 
up with a low concomitant imaging dose. This may benefit patients at low risk of 15 
recurrence who have a very good prognosis so imaging doses to non-target tissue 16 
should be kept as low as possible. Patients at high risk of recurrence may benefit from a 17 
dose escalation to excision cavity. Simultaneous integrated boost (SIB) is an obvious 18 
way to achieve this, but PTV margins probably need to be kept very small (in the region 19 
of 5 mm) to prevent excessive damage to normal tissues. In this patient group, a higher 20 
imaging dose may be accepted in order to achieve safe dose escalation to excision 21 
cavity. We have shown that an eNAL protocol with a total of 5 imaging sessions would 22 
enable a excision cavity margin of approximately 6mm, with an estimated total imaging 23 
dose of ~0.4cGy for a kV planar imaging system or ~25cGy using MVCT (Figure 1). To 24 
achieve a margin of less than 5 mm on-line imaging is required. This study has shown 25 
 19 
 
that deformation errors are small and further studies are required to measure delineation 1 
errors which are likely to be the greatest source of error.  2 
 3 
 20 
 
Conclusion 1 
 2 
This work has shown the relationship between PTV margin and estimated total dose 3 
from concomitant verification imaging, and their dependence on verification strategy for 4 
a cohort of breast cancer patients.  The deformation of the excision cavity requires a 5 
larger number of imaging days to reduce systematic errors to a given level however, 6 
deformation errors are small (less than 0.4mm). A boost or partial breast PTV margin of 7 
~10 mm, is possible with zero imaging dose and workload, however, high risk patients 8 
receiving simultaneous integrated boost radiotherapy with steep dose gradients, may 9 
benefit from a margin reduction of ~4mm with imaging doses from 0.4 cGy to 25 cGy 10 
using an eNAL protocol with ∆frep = 4 (a total of 5 imaging sessions). A NAL protocol with 11 
3 measurements gave an estimated margin of ~ 6 mm and may be suitable for low risk 12 
PBI patients.   13 
14 
 21 
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